Empagliflozin and metformin sustained-release tablet and preparation method thereof
By using the design of sustained release core, isolation layer and film-coated layer in empagliflozin metformin sustained release tablets, the uneven release and sudden release of metformin hydrochloride compound preparations was solved, and the smooth release of metformin hydrochloride was achieved. and the rapid release of engaliflozin improves the stability and safety of the drug.
Patent Information
- Application Number
- CN202411244329.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-06
- Publication Date
- 2024-11-12
AI Technical Summary
The existing compound preparation of empagliflozin metformin hydrochloride has uneven and sudden release phenomena, and the slow release stability of metformin hydrochloride gradually decreases over time, making it difficult to control the rapid release effect of empagliflozin, affecting the blood sugar control of patients. and safe.
The engagliflozin metformin sustained-release tablet including a sustained-release core, an isolation layer and a film-coated layer is used. The sustained-release tablet core consists of metformin hydrochloride, a binder and a sustained-release material. The isolation layer and the drug-on-release layer contain film-forming The material and the film-coated layer are Oppa's finished product. Through specific preparation processes and material proportion optimization, a skeleton sustained release mechanism is formed to achieve smooth sustained release drugs.
The constant rapid release of metformin hydrochloride was achieved for more than 12 hours, and about 90% of the drugs were released in equal proportions in the time period, avoiding sudden release after drinking, improving the dissolution rate and content uniformity of empagliflozin, and enhancing the patient's Compliance and security.
Smart Images

Figure CN118924693A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of preparation of empagliflozin metformin tablets, and particularly relates to an empagliflozin metformin sustained-release tablet and a preparation method thereof. Background Art
[0002] When metformin hydrochloride alone still cannot effectively control blood sugar, empagliflozin combined with metformin hydrochloride can improve blood sugar control in patients with type 2 diabetes on the basis of diet and exercise. However, due to the half-life of metformin hydrochloride, the common compound preparation of empagliflozin and metformin hydrochloride needs to be taken 2 or 3 times a day, while the single preparation of empagliflozin only needs to be taken once a day. The inconsistency in the number of medications has caused great trouble to patients. At the same time, since metformin hydrochloride is a highly soluble drug, the control It is imperative to release the drug to obtain a sustained-release preparation of metformin hydrochloride, and the sustained-release preparation has many advantages over ordinary preparations. The sustained-release preparation can maintain the blood drug concentration required for treatment for a long time, while reducing the peak-to-valley changes in blood drug concentration, reducing the incidence and severity of toxic and side effects. The sustained-release preparation can also improve patient compliance by reducing the number of times of taking the drug. The sustained-release mechanism of metformin hydrochloride sustained-release preparations is mainly divided into skeleton sustained-release mechanism, osmotic pump sustained-release mechanism, membrane-controlled sustained-release mechanism and pellet-type sustained-release mechanism.
[0003] Metformin hydrochloride has a very high water solubility, which makes it difficult to control the slow release rate of metformin hydrochloride in empagliflozin metformin combination preparations. Existing empagliflozin metformin combination preparations suffer from uneven and incomplete release of metformin hydrochloride. Even during the release process, if alcohol is consumed, there will be a problem of sudden release of metformin hydrochloride, which causes great irritation to the patient's gastrointestinal tract and causes fluctuations in blood drug concentrations. In severe cases, there is a risk of hypoglycemia, which endangers the patient's life. At the same time, since empagliflozin is a poorly soluble drug, empagliflozin metformin combination preparations also need to increase the dissolution rate of empagliflozin to ensure that empagliflozin in empagliflozin metformin combination preparations can achieve a rapid drug release effect.
[0004] Therefore, it is particularly important to prepare an empagliflozin-metformin compound preparation that has both the sustained-release effect of metformin hydrochloride and the rapid-release effect of empagliflozin, wherein the metformin hydrochloride still maintains good sustained-release stability after being placed, and does not cause a sudden release after drinking. Summary of the invention
[0005] The purpose of the present invention is to solve the problems of uneven release and burst release of metformin hydrochloride in the above-mentioned existing empagliflozin metformin compound preparations, and that the slow-release stability of metformin hydrochloride gradually decreases with time, and to provide an empagliflozin metformin sustained-release tablet and a preparation method.
[0006] The present invention relates to an empagliflozin metformin sustained-release tablet, which comprises a sustained-release tablet core and an isolation layer, a quick-release coating layer and a film coating layer; the sustained-release tablet core comprises metformin hydrochloride, an adhesive, a sustained-release material and a lubricant; the isolation layer comprises a film-forming material, an adhesive, a sunscreen and a pore-forming agent; the upper drug layer comprises empagliflozin and a film-forming material; and the film coating layer adopts an Opadry finished product.
[0007] Preferably, the binder includes one or more of starch, povidone, gelatin, polyethylene glycol, hydroxypropyl cellulose, and hypromellose.
[0008] Preferably, the sustained-release material includes one or more of carbomer, beeswax, hydroxypropyl methylcellulose, highly substituted hydroxypropyl cellulose, polyoxyethylene, sodium alginate, methylcellulose, and sodium carboxymethyl cellulose.
[0009] Preferably, the weight ratio of the sustained-release material to the adhesive in the sustained-release tablet core is 1:10-15.
[0010] Preferably, the weight ratio of the metformin hydrochloride to the empagliflozin is 100:0.5-5.
[0011] Preferably, the particle size of the metformin hydrochloride is controlled within the range of 60-150 mesh pharmacopoeia sieve.
[0012] Preferably, the particle size D90 value of the empagliflozin does not exceed 10 μm.
[0013] Preferably, the lubricant comprises one or more of magnesium stearate, colloidal silicon dioxide, and sodium stearyl fumarate. The isolation layer comprises one or more of hydroxypropyl methylcellulose, titanium dioxide, polydextrose, polyethylene glycol, talc, carnauba wax, purified water, ferric oxide, propylene glycol, and isopropyl alcohol; the upper drug layer comprises one or more of empagliflozin, hydroxypropyl methylcellulose, titanium dioxide, polydextrose, polyethylene glycol, and talc; and the film coating layer is a coating premix.
[0014] A method for preparing empagliflozin metformin sustained-release tablets, the steps of preparing the empagliflozin metformin sustained-release tablets are as follows:
[0015] Step 1: Use a universal grinder to grind metformin hydrochloride, and take the ground material through a rotary vibrating sieve.
[0016] Step 2: putting the metformin hydrochloride and the binder into a wet granulator and mixing;
[0017] Step 3: adding the premixed material and the binder into a wet granulator for granulation, and after granulation, using a swing granulator for granulation;
[0018] Step 4: adding the granules, the sustained-release material and the lubricant into a total mixer for mixing, and after mixing evenly, tableting to obtain the sustained-release tablet core;
[0019] Step 5: dissolving the isolation layer material in purified water, and coating the sustained-release tablet core using a high-efficiency coating machine to obtain the empagliflozin metformin sustained-release tablets.
[0020] Step 6: dissolving the empagliflozin and the upper drug layer material in purified water, and coating the isolation layer with a high-efficiency coating machine to obtain the empagliflozin metformin upper tablet.
[0021] Step seven: dissolving the coating powder in purified water, and coating the upper tablets using a high-efficiency coating machine to obtain the empagliflozin metformin sustained-release tablets.
[0022] Compared with the prior art, the advantages and positive effects of the present invention are:
[0023] Compared with the prior art, the empagliflozin metformin sustained-release tablets and preparation method of the present invention are
[0024] (1) The process first granulates metformin and then adds the sustained-release material. The sustained-release material can be well coated to form a skeleton. Compared with the membrane-controlled sustained-release and skeleton-controlled sustained-release of traditional metformin sustained-release tablets, the release is smoother and the constant-rate release exceeds 12 hours. About 90% of metformin is released at a constant rate. In addition, the process can control the sudden release in ethanol solution, and alcohol-drinking patients will not suffer from hypoglycemia caused by the sudden release of metformin hydrochloride.
[0025] (2) The particle size D90 value of empagliflozin in the drug layer does not exceed 10 μm. Since the drug layer is a suspension, the uniformity of the drug content is difficult to control. The optimization of the type and proportion of the film-forming material of the drug layer can more accurately control the uniformity of the content.
[0026] (3) The optimization of the film-forming material of the upper drug layer further improved the dissolution rate, providing great help for the rapid release of empagliflozin; BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 The release curve of metformin hydrochloride in pH 6.8 medium of the self-developed product in Example 1 Figure 2 The release curve of metformin hydrochloride of the self-developed product in Example 1 in a pH 1.2 medium (containing 40% ethanol solution) Figure 3 This is the release curve of empagliflozin in pH 6.8 medium of the self-developed product in Example 1 DETAILED DESCRIPTION
[0027] In order to more clearly understand the above-mentioned objects, features and advantages of the present invention, the present invention is further described below with reference to the accompanying drawings and embodiments.
[0028] In the following description, many specific details are set forth to facilitate a full understanding of the present invention. However, the present invention may also be implemented in other ways than those described herein. Therefore, the present invention is not limited to the specific embodiments of the following disclosure.
[0029] Example 1
[0030] formula:
[0031]
[0032]
[0033] Preparation steps:
[0034] Metformin hydrochloride is crushed by a universal grinder, and the crushed material is passed through a rotary vibrating screen. The metformin hydrochloride and the binder are put into a wet granulator for mixing; the premixed material and the binder are added to the wet granulator for granulation, and after the granulation is completed, a swing granulator is used for granulation; the particles, the sustained-release material, and the lubricant are added to the total mixer for mixing, and after mixing evenly, tablets are pressed to obtain the sustained-release tablet core; the isolation layer material is dissolved in purified water, and the sustained-release tablet core is coated with a high-efficiency coating machine to obtain the empagliflozin metformin sustained-release tablets. The empagliflozin and the upper drug layer material are dissolved in purified water, and the isolation layer is coated with a high-efficiency coating machine to obtain the empagliflozin metformin upper tablet. The coating powder is dissolved in purified water, and the upper tablet is coated with a high-efficiency coating machine to obtain the empagliflozin metformin sustained-release tablet.
[0035] Test Example 1
[0036] The samples in Example 1 and Comparative Example 1 were sampled for comparison of metformin hydrochloride dissolution curves. Release curve determination: According to the first method of the standard operating procedure for release test method, 900 ml of pH 6.8 phosphate buffer was used as the release medium, the rotation speed was 100 revolutions per minute, and the operation was carried out in accordance with the law. After 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 14 hours, 16 hours, 18 hours, 5 ml of the solution was taken respectively, filtered, and 5 ml of pH 6.8 phosphate buffer at the same temperature was immediately added to the dissolution cup; 1 ml of the subsequent filtrate was accurately measured respectively, placed in a 100 ml volumetric flask, diluted to the scale with pH 6.8 potassium dihydrogen phosphate buffer, shaken well, and the test sample was obtained. The f2 value method was used to measure the similarity of the release curves of metformin hydrochloride between the homemade preparation and the reference preparation. The test results are shown in Figure 1 , Figure 2 , Table 1, Table 2, RSD is the relative standard deviation.
[0037] Table 1 Example 1 Metformin hydrochloride release curve similarity comparison (f2 value method)
[0038]
[0039] Table 2 Uniformity of content of empagliflozin upper drug layer
[0040]
[0041]
[0042] from Figure 1 , Figure 2 , Table 1, Table 2 show that:
[0043] 1. In this embodiment, metformin hydrochloride is released slowly, and is released in equal proportion to the time period, which is highly consistent with the dissolution curve of the reference preparation, and f2 reaches 90;
[0044] 2. In this embodiment, the release of metformin hydrochloride in a pH 1.2 medium (configured into a 40% ethanol solution) is slower than that under normal conditions, and there is no sudden release, which can effectively avoid ethanol dose dumping (referring to the sudden release of modified-release preparations caused by taking alcoholic beverages and drugs together).
[0045] 3. In this embodiment, the empagliflozin upper drug layer of hypromellose is used as a film-forming material to enable rapid release of empagliflozin, and the hypromellose has a good suspending effect, which can evenly suspend empagliflozin therein, thereby significantly improving the content uniformity.
[0046] The above description is only a preferred embodiment of the present invention and does not limit the present invention in other forms. Any technician familiar with the profession may use the technical content disclosed above to change or modify it into an equivalent embodiment with equivalent changes for application in other fields. However, any simple modification or equivalent change made to the above embodiment based on the technical essence of the present invention without departing from the content of the technical solution of the present invention still falls within the protection scope of the technical solution of the present invention.
Claims
1. An empagliflozin metformin sustained-release tablet, It is characterized in that The sustained-release tablet comprises a sustained-release tablet core, an isolation layer, an upper drug layer and a film coating layer; the sustained-release tablet core comprises metformin hydrochloride, a sustained-release material, an adhesive, and a lubricant; the isolation layer comprises a film-forming material, an adhesive, a sunscreen, and a pore-forming agent; the upper drug layer comprises empagliflozin and a film-forming material; and the film coating layer adopts the finished product of Opadry.
2. The empagliflozin metformin sustained-release tablet according to claim 1, It is characterized in that The sustained-release material includes one or more of carbomer, beeswax, hydroxypropyl methylcellulose, highly substituted hydroxypropyl cellulose, polyoxyethylene, sodium alginate, methylcellulose, and sodium carboxymethyl cellulose.
3. The empagliflozin metformin sustained-release tablet according to claim 2, It is characterized in that The binder includes one or more of starch, povidone, gelatin, polyethylene glycol, hydroxypropyl cellulose, and hypromellose.
4. The empagliflozin metformin sustained-release tablet according to claim 3, It is characterized in that The lubricant includes one or more of magnesium stearate, colloidal silicon dioxide, and sodium stearyl fumarate.
5. The empagliflozin metformin sustained-release tablet according to claim 4, It is characterized in that The weight ratio of the metformin hydrochloride to the empagliflozin is 100:0.5-5.
6. The empagliflozin metformin sustained-release tablet according to claim 5, It is characterized in that The particle size of the metformin hydrochloride is controlled within the range of 60-150 mesh pharmacopoeia sieve.
7. The empagliflozin metformin sustained-release tablet according to claim 6, It is characterized in that The particle size D90 value of the empagliflozin is no more than 10 μm.
8. The empagliflozin metformin sustained-release tablet according to claim 7, It is characterized in that The isolation layer is one or more of hydroxypropyl methylcellulose, titanium dioxide, polydextrose, polyethylene glycol, talcum powder, carnauba wax, purified water, ferric oxide, propylene glycol, and isopropyl alcohol.
9. The empagliflozin metformin sustained-release tablet according to claim 8, It is characterized in that The upper drug layer is one or more of empagliflozin, hypromellose, titanium dioxide, polydextrose, polyethylene glycol, and talcum powder. The film coating layer is a coating premix.
10. A method for preparing empagliflozin metformin sustained-release tablets, It is characterized in that The steps for preparing the empagliflozin metformin sustained-release tablets according to claim 9 are as follows: Step 1: Use a universal grinder to grind metformin hydrochloride, and take the ground material through a rotary vibrating sieve. Step 2: putting the metformin hydrochloride and the binder into a wet granulator and mixing; Step 3: adding the premixed material and the binder into a wet granulator for granulation, and after granulation, using a swing granulator for granulation; Step 4: adding the granules, the sustained-release material and the lubricant into a total mixer for mixing, and after mixing evenly, tableting to obtain the sustained-release tablet core; Step 5: dissolving the isolation layer material in purified water, and coating the sustained-release tablet core using a high-efficiency coating machine to obtain the empagliflozin metformin sustained-release tablets. Step 6: dissolving the empagliflozin and the upper drug layer material in purified water, and coating the isolation layer with a high-efficiency coating machine to obtain the empagliflozin metformin upper tablet. Step seven: dissolving the coating powder in purified water, and coating the upper tablets using a high-efficiency coating machine to obtain the empagliflozin metformin sustained-release tablets.
11. A method for preparing empagliflozin metformin sustained-release tablets, It is characterized in that The steps for preparing the empagliflozin metformin sustained-release tablets according to claim 9 are as follows: Step 1: dissolving the adhesive in purified water to prepare an adhesive; Step 2: Add the metformin hydrochloride and the binder into a wet granulator and mix them evenly; then spray the binder into the granulator for granulation, and then use a swing granulator for granulation. The stirring frequency is 30Hz to 50Hz, the chopping frequency is 30Hz to 50Hz, and the granulation screen has a mesh size of 16 to 60. Step 3: After the particles are dried, the sustained-release material and the lubricant are added, mixed evenly, and then tabletted to obtain the sustained-release tablet core; Step 4: dissolving the isolation layer material in purified water, and coating the sustained-release tablet core using a high-efficiency coating machine to obtain the empagliflozin metformin sustained-release tablets. Step 5: dissolving the empagliflozin and the upper drug layer material in purified water, and coating the isolation layer with a high-efficiency coating machine to obtain the empagliflozin metformin upper tablet. Step six: dissolving the coating powder in purified water, and coating the upper tablets using a high-efficiency coating machine to obtain the empagliflozin metformin sustained-release tablets.
